Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
DJ Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
By Matt Grossman
Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.
The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.
Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.
Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.
Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 08, 2021 07:01 ET (11:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
DJ默克公司的抗癌藥物Keytruda在3期試驗中遇到主要終點
By Matt Grossman
馬特·格羅斯曼(Matt Grossman)著
Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.
總部位於新澤西州凱尼爾沃斯的默克公司(Merck&Co.Inc.)週四表示，該公司的Keytruda藥物達到了3期試驗的主要終點，該試驗旨在評估其在治療另一種癌症方面的使用情況。
The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.
這項試驗評估了Keytruda作為腎癌患者在腎切除、腎切除和轉移病灶切除後的輔助治療。腎切除術就是切除腎臟。在這項包括950名患者的試驗中，受試者接受了Keytruda或安慰劑。
Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.
默克説，與試驗中的安慰劑相比，Keytruda導致了無病生存率的顯著改善。研究人員將繼續評估試驗中患者的總體存活率。
Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.
默克研究實驗室首席醫療官Roy Baynes博士表示，該公司將盡快與監管機構分享試驗的詳細結果。
Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.
Keytruda，或pembrolizumab，已經在美國被批准用於治療其他形式的癌症。
Write to Matt Grossman at matt.grossman@wsj.com
寫信給馬特·格羅斯曼(Matt Grossman)，電子郵件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
April 08, 2021 07:01 ET (11:01 GMT)
2021年4月8日07：01美國東部時間(格林尼治標準時間11：01)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧